A systematic review of atypical antipsychotics in chronic pain management: Olanzapine demonstrates potential in central sensitization, fibromyalgia, and headache/migraine
The Clinical Journal of Pain May 24, 2018
Jimenez XF, et al. - Researchers performed a systematic review of all studies examining atypical antipsychotics (AAs) use for pain. They used 3 literature databases to search for word combinations of “pain” and a variety of commonly prescribed AAs ie, (olanzapine, quetiapine, risperidone, aripiprazole, ziprasidone, clozapine, paliperidone, iloperidone, lurasidone) and recognized only a few studies evaluating the analgesic effects of AAs. In multiple studies evaluating olanzapine in pain syndromes, preliminary and consistent efficacy of olanzapine in fibromyalgia and headache/migraine was noted. Other AAs eg, (quetiapine) failed to demonstrate efficacy in pain syndromes and/or lack robust study designs.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries